Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR5 | P35346 | 13/20 | 0.92 |
| ▸ | SSTR2 | P30874 | 15/20 | 0.88 |
| ▸ | SSTR4 | P31391 | 9/20 | 0.88 |
| ▸ | SSTR3 | P32745 | 3/20 | 0.78 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26270883 | 1.00 | SSTR5 (0.92) | SSTR5SSTR2SSTR4SSTR3SSTR1 | |
| SCHEMBL17404630 | 0.97 | SSTR2 (0.88) | SSTR5SSTR2SSTR4SSTR3SSTR1 | |
| SCHEMBL29383799 | 0.97 | SSTR2 (0.88) | SSTR5SSTR2SSTR4SSTR3SSTR1 | |
| SCHEMBL24588414 | 0.97 | SSTR2 (0.88) | SSTR5SSTR2SSTR4SSTR3SSTR1 | |
| SCHEMBL24211760 | 0.97 | SSTR2 (0.88) | SSTR5SSTR2SSTR4SSTR3SSTR1 | |
| SCHEMBL24211761 | 0.97 | SSTR2 (0.88) | SSTR5SSTR2SSTR4SSTR3SSTR1 | |
| SCHEMBL30379842 | 0.97 | SSTR2 (0.88) | SSTR5SSTR2SSTR4SSTR3SSTR1 | |
| SCHEMBL19605435 | 0.95 | SSTR5 (0.83) | SSTR5SSTR2SSTR4SSTR3SSTR1 | |
| SCHEMBL19542303 | 0.95 | SSTR5 (0.90) | SSTR5SSTR2SSTR4SSTR3SSTR1 | |
| SCHEMBL18712689 | 0.95 | SSTR2 (0.83) | SSTR5SSTR2SSTR4SSTR3SSTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 626 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026099626-A1 | METHODS AND SYSTEMS FOR MANUFACTURING RADIOPHARMACEUTICALS | NOVARTIS AG (CH) | 2026-05-15 | — | — | WO | claimed |
| US-20260117070-A1 | NEAR-INFRARED FLUORESCENT HEPTAMETHINE DYE CONJUGATES WITH FAVORABLE BLEACHING PROPERTIES | HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM GESUNDHEIT & UMWELT GMBH (DE) | 2026-04-30 | — | — | US | claimed |
| US-20260097140-A1 | Radiolabelled Compounds | UNIV MELBOURNE (AU) | 2026-04-09 | — | — | US | claimed |
| US-20250387523-A1 | COMBINATION THERAPY OF RADIONUCLIDE COMPLEX | NOVARTIS AG (CH) | 2025-12-25 | — | — | US | claimed |
| US-20250346589-A1 | RADIOISOTOPE LABELED SSTR2-AGONISTS WITH LINKERS | UNIV ERASMUS MED CT ROTTERDAM (NL) | 2025-11-13 | — | — | US | claimed |
| US-20250332301-A1 | STABLE, CONCENTRATED RADIOPHARMACEUTICAL COMPOSITION | NOVARTIS AG (CH) | 2025-10-30 | — | — | US | claimed |
| US-20250313579-A1 | LIGAND COMPOUNDS COMPRISING A CHELATING GROUP AS A BRIDGING GROUP | Technische Universität München (DE) | 2025-10-09 | — | — | US | claimed |
| US-20250288611-A1 | ICAM-1 TARGETED CAR CONSTRUCTS AND METHODS OF TREATMENT | AffyImmune Therapeutics Inc. | 2025-09-18 | — | — | US | claimed |
| EP-3368056-B1 | COMPOSITIONS AND METHODS FOR SENSITIZING LOW RESPONSIVE TUMORS TO CANCER THERAPY | PANDURANGI RAGHOOTTAMA (US) | 2025-08-20 | — | — | EP | claimed |
| EP-4590639-A1 | RADIOLABELLED COMPOUNDS | The University of Melbourne (AU) | 2025-07-30 | — | — | EP | claimed |
| WO-2022096673-A1 | COMBINATION OF PARA-AMINOHIPPURIC ACID (PAH) AND RADIOLABELED COMPLEXES FOR TREATING CANCER | ITM Isotopen Technologien München AG (DE) | 2022-05-12 | — | — | WO | claimed |
| WO-2022096103-A1 | COMBINATION OF PARA-AMINOHIPPURIC ACID (PAH) AND RADIOLABELED COMPLEXES FOR TREATING CANCER | ITM Isotopen Technologien München AG (DE) | 2022-05-12 | — | — | WO | claimed |
| EP-3965751-A1 | PARA-AMINOHIPPURIC ACID (PAH) AS A RENAL PROTECTIVE SUBSTANCE | ITM Isotope Technologies Munich SE (DE) | 2022-03-16 | — | — | EP | claimed |
| US-20220072166-A1 | METHOD OF TREATMENT OF NEUROENDOCRINE TUMORS | ADVANCED ACCELERATOR APPLICATIONS S.A. (FR) | 2022-03-10 | — | — | US | claimed |
| US-20220062386-A1 | Methods for Imaging and Treatment of Somatostatin-Receptor Positive Tumors | CORCEPT THERAPEUTICS INCORPORATED | 2022-03-03 | — | — | US | claimed |
| US-20220062447-A1 | RADIOPHARMACEUTICAL AND METHODS | CENTRE FOR PROBE DEVELOPMENT AND COMMERCIALIZATION (CA) | 2022-03-03 | — | — | US | claimed |
| WO-2022043754-A2 | RADIOPHARMACEUTICAL AND METHODS | CENTRE FOR PROBE DEVELOPMENT ANDCOMMERCIALIZATION (CPDC) (CA) | 2022-03-03 | — | — | WO | claimed |
| CN-114126654-A | Para-aminohippuric acid (PAH) as a kidney protective substance | 同位素技术慕尼黑有限公司 | 2022-03-01 | — | — | CN | claimed |
| WO-2022032353-A1 | RADIOPHARMACEUTICALS, USES THEREOF, AND METHODS FOR THE PRODUCTION THEREOF | Clarity Pharmaceuticals Ltd (AU) | 2022-02-17 | — | — | WO | claimed |
| EP-3941508-A1 | NON-HYDROLYZABLE, NON-CLEAVABLE, STABLE LINKERS FOR PRECISION THERAPEUTICS AND USES THEREOF | The Trustees of Columbia University in the City of New York (US) | 2022-01-26 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220062386-A1 | Methods for Imaging and Treatment of Somatostatin-Receptor Positive Tumors | SSTR3, SSTR1, SSTR4 | SSTR5 5/4885SSTR2 4/4885SSTR4 3/4885 |
| US-20250346589-A1 | RADIOISOTOPE LABELED SSTR2-AGONISTS WITH LINKERS | SSTR2, SSTR5, SSTR1 | SSTR5 2/4885SSTR2 1/4885SSTR4 5/4885 |
| US-20250332301-A1 | STABLE, CONCENTRATED RADIOPHARMACEUTICAL COMPOSITION | RAB5IF, TMEM14C, PAICS | SSTR5 164/4885SSTR2 418/4885SSTR4 519/4885 |
| US-20260097140-A1 | Radiolabelled Compounds | CA14, CA4, CA13 | SSTR5 212/4885SSTR2 474/4885SSTR4 56/4885 |
| US-20250387523-A1 | COMBINATION THERAPY OF RADIONUCLIDE COMPLEX | SSTR3, SSTR2, SSTR1 | SSTR5 5/4885SSTR2 2/4885SSTR4 9/4885 |
| US-20260117070-A1 | NEAR-INFRARED FLUORESCENT HEPTAMETHINE DYE CONJUGATES WITH FAVORABLE BLEACHING PROPERTIES | CBR1, CBR3, NR2E3 | SSTR5 115/4885SSTR2 327/4885SSTR4 222/4885 |
| US-20220072166-A1 | METHOD OF TREATMENT OF NEUROENDOCRINE TUMORS | IL15RA, IL15, SSTR5 | SSTR5 3/4885SSTR2 30/4885SSTR4 20/4885 |
| US-20250313579-A1 | LIGAND COMPOUNDS COMPRISING A CHELATING GROUP AS A BRIDGING GROUP | SHBG, SLC40A1, TFRC | SSTR5 110/4885SSTR2 204/4885SSTR4 161/4885 |
| US-20220062447-A1 | RADIOPHARMACEUTICAL AND METHODS | KIT, PROKR1, LPXN | SSTR5 4/4885SSTR2 8/4885SSTR4 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.